Do analysts prefer ADXS or BCDA?

BioCardia has a consensus target price of $25.00, indicating a potential upside of 2,258.49%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ADXS or BCDA more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A BioCardia N/A -5,456.14% -232.75%

Do analysts recommend GRML or BCDA?

BioCardia has a consensus price target of $25.00, indicating a potential upside of 2,258.49%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Greenland Mines Ltd. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GRML or BCDA more profitable?

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Greenland Mines Ltd. Common Stock N/A -109.40% -98.80% BioCardia N/A -5,456.14% -232.75%

Does the media prefer GRML or BCDA?

In the previous week, BioCardia had 2 more articles in the media than Greenland Mines Ltd. Common Stock. MarketBeat recorded 6 mentions for BioCardia and 4 mentions for Greenland Mines Ltd. Common Stock. BioCardia's average media sentiment score of 0.50 beat Greenland Mines Ltd. Common Stock's score of 0.10 indicating that BioCardia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenland Mines Ltd. Common Stock 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCardia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PYRGF or BCDA?

BioCardia has a consensus target price of $25.00, indicating a potential upside of 2,258.49%. Given BioCardia's stronger consensus rating and higher probable upside, analysts plainly believe BioCardia is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer PYRGF or BCDA?

In the previous week, BioCardia had 5 more articles in the media than PyroGenesis Canada. MarketBeat recorded 6 mentions for BioCardia and 1 mentions for PyroGenesis Canada. BioCardia's average media sentiment score of 0.50 beat PyroGenesis Canada's score of 0.00 indicating that BioCardia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCardia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BCDA or GRCE more profitable?

Grace Therapeutics' return on equity of -14.45% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Grace Therapeutics N/A -14.45% -13.58%

Does the media favor BCDA or GRCE?

In the previous week, BioCardia had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 6 mentions for BioCardia and 3 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.00 beat BioCardia's score of 0.50 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grace Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioCardia (BCDA) Competitors

$1.06 +0.06 (+6.00%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$1.14 +0.08 (+7.74%)

As of 06/24/2026 08:00 PM Eastern

Compare

BCDA vs. BTAI, ADXS, GRML, PYRGF, and GRCE

Should you buy BioCardia stock or one of its competitors? MarketBeat compares BioCardia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioCardia include BioXcel Therapeutics (BTAI), Ayala Pharmaceuticals (ADXS), Greenland Mines Ltd. Common Stock (GRML), PyroGenesis Canada (PYRGF), and Grace Therapeutics (GRCE). These companies are all part of the "pharmaceutical products" industry.

How does BioCardia compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, BioCardia had 6 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 6 mentions for BioCardia and 0 mentions for BioXcel Therapeutics. BioCardia's average media sentiment score of 0.50 beat BioXcel Therapeutics' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
BioCardia	Positive

BioXcel Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

BioCardia has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
BioCardia	N/A	-5,456.14%	-232.75%

BioXcel Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 739.69%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 2,258.49%. Given BioCardia's higher probable upside, analysts clearly believe BioCardia is more favorable than BioXcel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by insiders. Comparatively, 17.4% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioCardia has lower revenue, but higher earnings than BioXcel Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	63.21	-$69.90M	-$5.75	N/A
BioCardia	$60K	201.05	-$8.23M	-$0.91	N/A

Summary

BioCardia beats BioXcel Therapeutics on 9 of the 16 factors compared between the two stocks.

How does BioCardia compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 17.4% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioCardia has a consensus target price of $25.00, indicating a potential upside of 2,258.49%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioCardia has lower revenue, but higher earnings than Ayala Pharmaceuticals. BioCardia is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
BioCardia	$60K	201.05	-$8.23M	-$0.91	N/A

In the previous week, BioCardia had 6 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 6 mentions for BioCardia and 0 mentions for Ayala Pharmaceuticals. BioCardia's average media sentiment score of 0.50 beat Ayala Pharmaceuticals' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
BioCardia	Positive

Ayala Pharmaceuticals' return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
BioCardia	N/A	-5,456.14%	-232.75%

Ayala Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Summary

BioCardia beats Ayala Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does BioCardia compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by insiders. Comparatively, 17.4% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BioCardia has higher revenue and earnings than Greenland Mines Ltd. Common Stock. BioCardia is trading at a lower price-to-earnings ratio than Greenland Mines Ltd. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
BioCardia	$60K	201.05	-$8.23M	-$0.91	N/A

In the previous week, BioCardia had 2 more articles in the media than Greenland Mines Ltd. Common Stock. MarketBeat recorded 6 mentions for BioCardia and 4 mentions for Greenland Mines Ltd. Common Stock. BioCardia's average media sentiment score of 0.50 beat Greenland Mines Ltd. Common Stock's score of 0.10 indicating that BioCardia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenland Mines Ltd. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCardia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
BioCardia	N/A	-5,456.14%	-232.75%

BioCardia has a consensus price target of $25.00, indicating a potential upside of 2,258.49%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Greenland Mines Ltd. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Greenland Mines Ltd. Common Stock has a beta of 6.94, suggesting that its share price is 594% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

Summary

BioCardia beats Greenland Mines Ltd. Common Stock on 9 of the 14 factors compared between the two stocks.

How does BioCardia compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and BioCardia (NASDAQ:BCDA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, BioCardia had 5 more articles in the media than PyroGenesis Canada. MarketBeat recorded 6 mentions for BioCardia and 1 mentions for PyroGenesis Canada. BioCardia's average media sentiment score of 0.50 beat PyroGenesis Canada's score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCardia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCardia has a consensus target price of $25.00, indicating a potential upside of 2,258.49%. Given BioCardia's stronger consensus rating and higher probable upside, analysts plainly believe BioCardia is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioCardia has lower revenue, but higher earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.58	-$21.12M	-$0.04	N/A
BioCardia	$60K	201.05	-$8.23M	-$0.91	N/A

BioCardia has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
BioCardia	N/A	-5,456.14%	-232.75%

PyroGenesis Canada has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

BioCardia beats PyroGenesis Canada on 11 of the 16 factors compared between the two stocks.

How does BioCardia compare to Grace Therapeutics?

BioCardia (NASDAQ:BCDA) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Grace Therapeutics has lower revenue, but higher earnings than BioCardia. Grace Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	201.05	-$8.23M	-$0.91	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

Grace Therapeutics' return on equity of -14.45% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Grace Therapeutics	N/A	-14.45%	-13.58%

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,258.49%. Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 157.51%. Given BioCardia's higher probable upside, equities research analysts clearly believe BioCardia is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioCardia has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

In the previous week, BioCardia had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 6 mentions for BioCardia and 3 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.00 beat BioCardia's score of 0.50 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grace Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioCardia beats Grace Therapeutics on 7 of the 12 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCDA vs. The Competition

Export

Metric	BioCardia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.38M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-1.16	20.50	25.39	23.96
Price / Sales	201.05	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	13.25	8.26	10.76	6.41
Net Income	-$8.23M	$23.91M	$3.56B	$337.14M
7 Day Performance	11.86%	3.05%	1.37%	-0.48%
1 Month Performance	10.99%	2.40%	0.81%	0.49%
1 Year Performance	-51.38%	56.35%	30.53%	28.16%

BioCardia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCDA BioCardia	3.9997 of 5 stars	$1.06 +6.0%	$25.00 +2,258.5%	-51.4%	$11.38M	$60K	N/A	40	Gap Down
BTAI BioXcel Therapeutics	1.8755 of 5 stars	$1.20 +3.4%	$11.00 +816.7%	-24.3%	$35.82M	$640K	N/A	90
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
GRML Greenland Mines Ltd. Common Stock	0.463 of 5 stars	$0.32 +12.2%	N/A	-84.2%	$34.92M	N/A	N/A	5
PYRGF PyroGenesis Canada	N/A	$0.17 -0.5%	N/A	-55.5%	$34.48M	$9.14M	N/A	90	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCDA) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCardia (BCDA) Competitors

BCDA vs. BTAI, ADXS, GRML, PYRGF, and GRCE

How does BioCardia compare to BioXcel Therapeutics?

Summary

How does BioCardia compare to Ayala Pharmaceuticals?

Summary

How does BioCardia compare to Greenland Mines Ltd. Common Stock?

Summary

How does BioCardia compare to PyroGenesis Canada?

Summary

How does BioCardia compare to Grace Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCardia (BCDA) Competitors

BCDA vs. BTAI, ADXS, GRML, PYRGF, and GRCE

How does BioCardia compare to BioXcel Therapeutics?

Does the media prefer BTAI or BCDA?

Which has more volatility & risk, BTAI or BCDA?

Is BTAI or BCDA more profitable?

Do analysts prefer BTAI or BCDA?

Do institutionals & insiders believe in BTAI or BCDA?

Which has better valuation & earnings, BTAI or BCDA?

Summary

How does BioCardia compare to Ayala Pharmaceuticals?

Do insiders and institutionals believe in ADXS or BCDA?

Do analysts prefer ADXS or BCDA?

Which has preferable valuation and earnings, ADXS or BCDA?

Does the media prefer ADXS or BCDA?

Is ADXS or BCDA more profitable?

Which has more risk & volatility, ADXS or BCDA?

Summary

How does BioCardia compare to Greenland Mines Ltd. Common Stock?

Do institutionals & insiders believe in GRML or BCDA?

Which has stronger earnings and valuation, GRML or BCDA?

Does the media prefer GRML or BCDA?

Is GRML or BCDA more profitable?

Do analysts recommend GRML or BCDA?

Which has more risk & volatility, GRML or BCDA?

Summary

How does BioCardia compare to PyroGenesis Canada?

Does the media prefer PYRGF or BCDA?

Do analysts recommend PYRGF or BCDA?

Which has better valuation and earnings, PYRGF or BCDA?

Is PYRGF or BCDA more profitable?

Which has more volatility & risk, PYRGF or BCDA?

Do institutionals and insiders believe in PYRGF or BCDA?

Summary

How does BioCardia compare to Grace Therapeutics?

Which has preferable valuation & earnings, BCDA or GRCE?

Is BCDA or GRCE more profitable?

Do analysts rate BCDA or GRCE?

Do institutionals & insiders hold more shares of BCDA or GRCE?

Which has more volatility & risk, BCDA or GRCE?

Does the media favor BCDA or GRCE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools